REG - Diaceutics PLC - Contract Win

DiaceuticsAnnouncement

14/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211214:nRSN5055Va&default-theme=true

RNS Number : 5055V  Diaceutics PLC  14 December 2021

14 December 2021

Diaceutics PLC

("Diaceutics" or "the Company")

Contract win

US$1m contract with leading life sciences company for data feed from the DXRX
platform

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is
pleased to announce that it has secured a five year subscription contract with
a top five global life sciences company, a global leader in diagnostics, to
deliver customised data insights via the DXRX platform. The total contract
value is in excess of $1m spread across five years and subject to milestones
in year 1 and year 3. This contract demonstrates the demand for customised
real-world data to support sales and marketing initiatives for leading life
science companies, the applicability of the Company's offering to businesses
outside of its core pharma customer base, and supports the move towards
enhanced subscription-based revenues, a key strategy for the Company going
forward.

The contract will see Diaceutics deliver real-world data and insights on the
demand for biomarkers customised to the client's needs across a number of
diseases. This information will help the customer to identify important
biomarker adoption trends and gaps which can support the commercialisation of
new and existing diagnostics.

The data will be supplied from DXRX, the world's first diagnostic
commercialisation platform for Precision Medicine, which uses machine learning
to integrate output of real-world, real time diagnostic testing data from a
global network of laboratories.

Peter Keeling, CEO and Founder of Diaceutics PLC, commented:

"This multi-year deal demonstrates the confidence which one of the
acknowledged global leaders in diagnostics has in the quality of our Deductive
Diagnostic Pathways, and the strength of the DXRX platform.

"This agreement represents another step towards our recurring, high margin and
scalable multi-year subscription revenue targets and reinforces our belief in
the opportunity for the DXRX platform, to serve multiple stakeholders across
healthcare industry unlock the promise of Precision Medicine."

 

Enquiries:

 Diaceutics PLC
 Philip White, Chief Financial Officer                Via Alma PR

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison, Stewart Wallace, Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde, Kieran Breheny, Matthew Young        diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

Diaceutics' proprietary Deductive Diagnostic Pathways (DDPs) translate
millions of complex data points into valuable actionable insights enabling
pharmaceutical customers to understand the testing journey for patients across
multiple disease types and identify real world data trends.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTMZMMZRFRGMZM